Document:

exv10w9

 

Exhibit 10.9

Amended and Restated Employment Agreement

April 21, 2005

Dave Bol, Ph.D.

Dear Dave:

This Amended and Restated Employment Agreement (this “Agreement”), on its Effective Date (as
defined below), amends, restates and supercedes your prior Letter of Employment dated April 7,
2005 between Avalon Pharmaceuticals, Inc. (the “Company”) and you (the “Prior Letter Agreement”).
This Agreement shall be effective and shall supercede the Prior Letter Agreement concurrently with
the effective date of the first registration statement filed by the Company to register shares of
its common stock for sale to the public through one or more underwriters (the “Effective Date”).
Notwithstanding the foregoing, this Agreement shall not become effective, shall be deemed null and
void and shall not supercede the Prior Letter Agreement if (i) the Effective Date does not occur
prior to January 1, 2006 or (ii) your employment is terminated by the Company or by you for any
reason prior to the Effective Date. If this Agreement does not become effective, the Prior Letter
Agreement shall remain in full force and effect in accordance with its terms. The terms of your
employment are as follows:

	 	 	 
	Title:

	 	Vice President of Pharmaceutical Development
	 
	 	 
	Reporting to:

	 	Kenneth C. Carter, President & CEO
	 
	 	 
	Initial Starting

Salary:

	 	$195,000 per annum, subject to adjustment from time to
time in the Company’s discretion
	 
	 	 
	Classification:

	 	Exempt
	 
	 	 
	Equity:

	 	Subject to the approval of the Compensation Committee of
the Company’s Board of Directors, the Company will grant
you options for an additional 145,125 shares of Avalon
Pharmaceuticals, Inc. Common Stock under the Company’s
Stock Option Plan at the current market price on the date
of grant. These options will vest over a four (4) year
period. The terms and conditions for any options will be
those in the Company’s Plan, or as set by the Board.

 

 

	 	 	 
	Bonus Plan:

	 	Eligibility and distribution of bonus is based on the
achievement of corporate and individual objectives in
accordance with the approved Avalon Pharmaceuticals
Compensation Plan. You will be eligible for a bonus up to
25% of your base pay depending upon the completion of the
approved goals.
	 
	 	 
	Benefits:

	 	The Company provides a comprehensive benefits program,
which includes standard medical and dental benefits, long-
and short-term disability coverage, a 401(K) plan, and a
flexible benefits plan. Paid time off is also available to
all employees. These programs will be provided in
accordance with the terms and conditions set forth in each
plan, and are subject to change at the Company’s
discretion. You will continue to receive these benefits,
which have been previously provided to you during your
employment at Avalon. Provided that underwriting approves
your application, you will also receive benefit of
Avalon’s salary continuation plan for executives.
	 
	 	 
	Termination:

	 	Upon termination for any reason, the Company shall pay you
within two weeks of such termination, your current base
salary earned through the termination date, plus accrued
vacation, if any, and other benefits or payments, if any,
to which you are entitled as provided in accordance with
the terms and conditions of such benefit plan. In the
event you are terminated by the Company without “Cause”
(as herein defined), or if you terminate your employment
with the Company for “Good Reason” (as hereinafter
defined), continue to pay you your bi-weekly rate in
effect at the time of termination for a period of six (6)
months (“Severance”); provide you with outplacement
services; provide and pay the Company’s portion of your
health insurance for a period of six months following such
termination. You shall not be required to mitigate damages
by seeking employment elsewhere. If you are terminated
with cause, the Company shall pay you only your current
base salary earned through the termination date, plus
accrued vacation, if any, to which you are entitled as
provided in accordance with the terms and conditions of
such benefit plan.

 

 

	 	 	 
	

	 	“Cause” shall include (i) your conviction of a felony, either in
connection with the performance of your obligations to the Company or
otherwise, which adversely affects your ability to perform such
obligations or materially adversely affects the business activities,
reputation, goodwill or image of the Company, (ii) your willful
disloyalty, deliberate dishonesty, breach of fiduciary duty to the company
(iii) your breach of the terms of this Agreement, or your failure or
refusal to use your best efforts to carry out any material tasks that do
not violate any other term of this agreement, provided such tasks are
assigned to you by the Company in accordance with the terms hereof, which
breach or failure continues for a period of more than thirty (30) days
after your receipt of written notice thereof from the Company, (iv) the
commission by you of any act of fraud, embezzlement or
deliberate disregard of a rule or policy of the Company known to you or
contained in a policy and procedure manual provided to you which results
in material loss, damage or injury to the Company, or (v) the material
breach by you of any of the material provisions of the Confidentiality
Assignment of Inventions and Non-Competition Agreement.
	 
	 	 
	

	 	Termination of your employment by you shall constitute termination for
“Good Reason” if such termination occurs (a) within eighteen months of a
“Change in Control” (as hereinafter defined) (b) within three months of a
material diminution in your responsibilities as VP Pharmaceutical
Development (provided that such diminution is not in connection with the
termination of your employment for Cause), (c) within three months of your
principal work location changing to be more than 50 miles from your
current residence; or (d) in the event you should die while an employee of
the Company. The Company shall notify you, within 10 days of receipt of
your notice of intent to terminate your employment for Good Reason, if the
Company disagrees with your intent to terminate pursuant to this
paragraph.
	 
	 	 
	

	 	A “Change in Control” shall be deemed to have occurred if either: (i) any
“person” (including, without limitation, any individual, sole
proprietorship, partnership, trust, corporation, association, joint
venture, or other entity, whether or not incorporated), or “group” of
persons (as

 

 

	 	 	 
	

	 	such terms are used in Sections 13(d) and 14(d) of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”)),
becomes, after the date hereof, the “beneficial owner” (as defined in Rule
13d-3 under the Exchange Act), directly or indirectly, of securities of
the Company representing fifty percent (50%) or more of the combined
voting power of the Company’s then outstanding securities; (ii) during any
two (2) year period, individuals who constitute the Board of Directors at
the beginning of such period, together with any new directors elected or
appointed during the period whose election or appointment resulted from a
vacancy on the Board of Directors caused by the retirement, death, or
disability of a director and whose election or appointment was approved by
a vote of at least a majority of the directors then still in office who
were directors at the beginning of the period, cease for any reason to
constitute a majority of the Board of Directors; (iii) the Company sells,
assigns, conveys, transfers, leases or otherwise disposes of all or
substantially all of its assets to any person; (iv) the Company
consolidates with, or merges with or into another entity, or any entity
consolidates with, or merges with or into, the Company (a “Merger”), in
which the owners of outstanding voting stock of the Company immediately
prior to such Merger do not represent at least a majority of the voting
power in the surviving entity after the Merger; or (v) the stockholders of
the Company approve a plan of liquidation or dissolution.
	 
	 	 
	Conflict:

	 	You hereby acknowledge that you are not a party to
any agreement that in any way prohibits or imposes any restrictions on your
employment with the Company, and your acceptance hereof will not breach any
agreements to which you are a party.
	 
	 	 
	Other Provisions:

	 	Continued employment will be contingent
upon your signing the Avalon Pharmaceuticals, Inc. Confidentiality, Assignment
of Inventions and Non-Competition Agreement dated August 13, 2002. You also
agree to be bound by all personnel policies that may be adopted from time to
time. Finally, you will remain an employee at will, meaning you are not
obligated to remain employed at the company for any specific period of time.
Likewise, the

 

 

	 	 	 
	

	 	Company is not obligated to employ you for any specific period.

Sincerely,

ON BEHALF OF AVALON PHARMACEUTICALS, INC.:

	 	 	 
	/s/
Kenneth C. Carter
	 	April 21, 2005
	 

	 	 
	Kenneth C. Carter

President & CEO

	 	Date
	 
	 	 
	ACCEPTED:
	 	 
	   
	 	 
	/s/
David Bol
	 	April 21, 2005
	   

	 	 
	David Bol, Ph.D.

	 	Dateexv10w10a

 

Exhibit 10.10A

CONSULTING AGREEMENT

This CONSULTING AGREEMENT (the “Agreement”) effective as of this 1st day of February,
2000, and entered into by and between Therapeutic Genomics, Inc., a Delaware corporation with a
place of business at 9700 Great Seneca Highway, Rockville, Maryland 20853 (“TGI”) and Bradley G.
Lorimier, an individual with an address at 7807 Fox Gate Court, Bethesda, Maryland 20817
(“Consultant”).

WHEREAS, TGI is in the business of discovering genetic targets for cancer drug discovery and
discovering and developing such cancer drugs; and

WHEREAS, Consultant is desirous of providing consulting services to TGI; and

WHEREAS, TGI is desirous of retaining Consultant.

NOW, THEREFORE, in consideration of the mutual promises and other good and valuable
consideration, the parties hereby agree as follows:

1. Engagement. TGI hereby appoints Consultant, and Consultant hereby accepts
such appointment, upon the terms and conditions set forth herein.

2. Services. The nature of the services to be provided by Consultant and the
compensation Consultant shall receive from TGI are set forth in Exhibit A, attached and
incorporated herein by reference.

3. Term. The term of this Agreement shall commence on the 1st day of February,
2000 and shall continue until the 31th day of January, 2003 or until terminated as set
forth below.

4. Independent Contractor. The parties expressly intend and agree that Consultant is
acting as an independent contractor and not as an employee of TGI. Under no circumstances shall
Consultant look to TGI as his employer, or as a partner, agent, or principal. Consultant will
determine the method, details and means of performing the services
for TGI subject to TGI approval.

5. Confidentiality. As a condition of this Agreement, Consultant will enter into a
Confidentiality Agreement with TGI attached hereto as Exhibit A and incorporated herein by this
reference.

6. Termination.

6.1 Termination. Either party may terminate this Agreement at any time by
giving ninety (90) days written notice to the other party. In the event of the termination
of this Agreement in accordance with the provisions of this Section 6.1, no payments made
to Consultant shall be refunded or returned, and all payments due through the end of the
90-day period shall be made promptly.

 

 

6.2 Remedies Upon Breach. In the event of any breach of this Agreement by
either party, the other party shall have the right to terminate the Agreement by thirty
(30) days written notice to the breaching party. Such party shall also be entitled, if it
so elects, to institute and prosecute proceedings in any court of competent jurisdiction,
either in law or in equity, to enjoin the breaching party from violating any of the terms
of this Agreement, to enforce by specific performance any of the terms of this Agreement,
and to obtain damages, or any of these aforementioned remedies, but nothing herein
contained shall be construed to prevent such remedy or combination of remedies as such
party may elect to invoke. The failure of a party to promptly institute legal action upon

breach of this Agreement shall not constitute a waiver of that or any other breach hereof.

6.3 Return of Materials at Termination. In the event of any termination of
Consultant’s appointment, with or without cause, Consultant shall promptly deliver to TGI
any and all materials, property, documents, data, and all other information belonging to
TGI or pertaining to proprietary information of TGI, whether prepared by TGI of Consultant.
Consultant shall not take any materials, property, documents or other information, or any
reproduction or excerpt thereof, belonging to TGI or pertaining to any proprietary
information of TGI.

7. General Provisions.

7.1 Entire Agreement. This Agreement constitutes the entire and exclusive
Agreement between the parties with respect to the subject matter hereof and supersedes any
prior or contemporaneous agreements, representations and understandings of the parties with
respect thereto.

7.2 Amendments. No Amendment or modification of the terms or conditions of this
Agreement shall be valid unless in writing and signed by the parties hereto.

7.3 Severability. If any provision of this Agreement shall be held illegal or
unenforceable, the validity, legality or enforceability of the remaining provisions of this
Agreement shall not in any way be affected or impaired thereby.

7.4 Waiver. The failure of any party hereto to insist upon strict compliance of any
provision of this Agreement or to exercise any right hereunder will not constitute a waiver
of that provision or right.

7.5 Representations and Warranties. Consultant represents and warrants that
to the best of his knowledge he is permitted to enter into this Agreement and perform the
obligations contemplated thereby and that this Agreement and the terms and obligations
thereof are not inconsistent with any obligation he may have.

 

 

7.6 Confidential Information. Consultant represents and warrants and agrees
that he can and will perform the services required by this Agreement without disclosing
or using any confidential information and/or proprietary Information
of a third party.

7.7
Successors and Assigns. The lights and obligations of TGI under this
Agreement shall inure to the benefit of and shall be binding upon the successors and
assigns of TGL. Consultant shall not be entitled to assign any of Consultant’s rights or
obligations under this Agreement.

7.8 Taxes. Consultant shall pay, when and as due, any and all taxes incurred as
a result of Consultant’s compensation hereunder, including estimated taxes, and if
required by TGI, agrees to provide TGI with proof of said payment.

7.9 Governing Law. This Agreement shall be interpreted, construed,
governed and enforced according to the laws of the State of Maryland without giving
effect to its conflict of laws principles.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the effective date set forth
above.

	 	 	 	 	 	 	 	 	 
	THERAPEUTIC GENOMICS, INC.	 	 	 	BRADLEY G. LORIMIER	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Kenneth C. Carter
	 	 	 	/s/ Bradley G. Lorimier	 	 
	

	 	 
	 	 	 	 	 	 
	

	 	Kenneth C. Carter	 	 	 	 	 	 
	

	 	President and Chief Executive Officer	 	 	 	 	 	 

 

 

Exhibit A

Nature of Services:

	1.  	Consultant shall assist TGI as a general business consultant and as a business
development and licensing consultant to seek alliances and/or licensing arrangements
with various companies in the pharmaceutical industry. Consultant shall be available to
TGI for such consulting for an average of two (2) days per month during the term of the
Agreement.

Compensation:

	1.  	In consideration of the services provided by Consultant to TGI under this Agreement,
TGI shall pay Consultant an amount of five thousand dollars ($5,000) per month during
the term of this Agreement, which amount shall be payable on the last day of each
calendar month.
	 
	2.  	TGI shall grant to Consultant on the Effective Date of Agreement fifty thousand
(55,000) options to purchase shares of TGI common stock at fair market value, as
determined by the TGI Board of Directors, exercisable over ten (10) years, and vested as
follows:

	 	 	 	 	 
	Shares	 	Vesting	 
	15,000
	 	Effective Date of the
	 
	 	Agreement
	 
	 	 
	10,000
	 	1st Anniversary
	 
	 	 
	10,000
	 	2nd Anniversary
	 
	 	 
	20,000
	 	Completion of first major
	 
	 	pharmaceutical collaboration
	 
	 	agreement or first product
	 
	 	licensing agreement as
	 
	 	mutually agreed by parties

	3.  	TGI shall reimburse Consultant for reasonable business expenses incurred in the
performance of services under this Agreement within thirty (30) days of receipt of an
accounting thereof.
	 
	4.  	Consultant’s Social Security Number is ###-##-####.

 

 

Exhibit B

To Consulting Agreement Between

Therapeutic Genomics, Inc. and Bradley G. Lorimier

CONFIDENTIALITY, ASSIGNMENT OF INVENTIONS AND NON-

COMPETITION AGREEMENT FOR CONSULTANT LORIMIER

     This Confidentiality, Assignment of Inventions and Non-Competition Agreement is made as of
the___________________  day of February, 2000 by and between Therapeutic Genomics, Inc., a Delaware corporation (Company),
and Bradley G. Lorimier (Consultant).

     WHEREAS, the Consultant is a consultant of the Company; and

     WHEREAS, the Company has developed, and the Company and/or Consultant may continue to develop
during the period Consultant is retained by the Company, certain Proprietary Information,
Inventions and Intellectual Property (as those terms are hereinafter defined), that the Company
wishes to protect and maintain as confidential; and

     WHEREAS, the Company from time to time has received, and may continue to receive during the
period Consultant is so retained by the Company, the Proprietary Information of others, and the
Company wishes, and is (in certain circumstances) contractually obligated, to maintain the
confidentiality of such Proprietary Information; and

     WHEREAS, the Company has developed, and will continue to develop during the period Consultant
is so retained by the Company, goodwill by, among other things, substantial expenditure of money
and effort;

     NOW, THEREFORE, in consideration of the premises and the mutual covenants and undertakings
contained in this agreement, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, IT IS AGREED:

 1. Definitions. As used in this Agreement, the following terms shall have the following
meanings:

	 	(a)  	Agreement means this confidentiality and non-competition agreement, including
all exhibits, schedules and annexations, as all may be amended from time to time in the
manner provided in this Agreement.
	 
	 	(b)  	Consultancy means the current or anticipated or subsequent retention of Consultant
by the Company as a full-time Consultant, a part-time Consultant, or otherwise, or any
other period during which Consultant receives compensation from the company in any
capacity.
	 
	 	(c)  	Intellectual Property means any Invention, writing, trade name, trademark, service
mark or any other material registered or otherwise protected or protectible under state,
federal, or foreign patent, trademark, copyright, or similar laws.
	 
	 	(d)  	Inventions include ideas, discoveries, inventions, developments and improvements,
whether or not reduced to practice and whether or not patentable or otherwise within the
definition of Intellectual Property.
	 
	 	(e)  	Proprietary Information includes any scientific, technical, trade or business secrets of
the Company and
any scientific, technical, trade or business materials that the Company treats, or is
obligated to treat, as confidential or proprietary, including, but not limited to,
Inventions belonging to the Company and

1

 

confidential information obtained by or given to the Company about or belonging to its
suppliers, licensors, licensees, partners, affiliates, customers, potential customers or
others.

	2.  	Consultant Acknowledgments. The Company has developed and will develop its Proprietary
Information and Intellectual Property over a substantial period of time and at a substantial
expense, and its Proprietary Information and Intellectual Property are integral to the
goodwill of the Company. During the course of Consultancy to the Company, Consultant may
develop or become aware of Proprietary Information and/or Intellectual Property. Protection of
the Proprietary Information and Intellectual Property is necessary to the conduct of the
Company’s business, and the Company is and shall at all times remain the sole owner of the
Company’s Proprietary Information and Intellectual Property.
	 
	3.  	Confidentiality. Consultant shall at all times, both during and after any termination of
Consultant’s Consultancy by the Company by either the Company or Consultant, maintain in
confidence and not utilize the Proprietary Information or the Intellectual Property of the
Company, and/or technology or proprietary information of others under confidential evaluation
by the Company except in performing services for the Company pursuant to his Consultancy.
Maintaining such Proprietary Information and Intellectual Property in confidence shall include
refraining from disclosing such Proprietary Information or Intellectual Property to any third
party (except when duly and specifically authorized in writing to do so for purpose of
furthering the business of the Company), and refraining from using such Proprietary
Information or Intellectual Property for the account of Consultant or for any other person or
business entity. Consultant will not file patents based on the Company’s technology or
confidential information, nor seek to make improvements thereon, without the Company’s written
approval. Consultant agrees not to make any copies of the Proprietary Information or
Intellectual Property of the Company (except when appropriate for the furtherance of the
business of the Company or duly and specifically authorized to do so) and promptly upon
request, whether during or after the period of Consultancy by the Company, to return to the
Company any and all documentary, machine-readable or other elements of evidence of such
Proprietary Information, Intellectual Property, and any copies of either that may be in
Consultant’s possession or under Consultant’s control.
	 
	4.  	Rights to Inventions and Intellectual Property. In connection with Consultant’s
Consultancy by the Company, or by use of the resources of the Company, whether or not
Consultant is then retained by the Company. Consultant may produce, develop, create, invent,
conceive or reduce to practice Inventions and Intellectual Property related to the business of
the Company. Consultant shall maintain and furnish to the Company complete and current
records of all such Inventions and Intellectual Property. Consultant agrees that all such
Inventions and Intellectual Property are and shall be the exclusive property of the Company,
and that the Company may use or pursue them without restriction or
additional compensation.
Consultant: (i) hereby assigns, sets over and transfers to the Company all of his right,
title and interest in and to such Inventions and Intellectual Property; (ii) agrees that
Consultant and his agents shall, during and after the period Consultant is retained by the
Company, cooperate fully in obtaining patent, trademark, service mark, copyright or other
proprietary protection for such Inventions and Intellectual Property, all in the name of the
Company (but only at Company expense), and, without limitation, shall execute all requested
applications, assignments and other documents in furtherance of obtaining such protection or
registration and confirming full ownership by the Company of such Inventions and Intellectual
property; and (iii) shall, upon leaving the Company, provide to the Company in writing a full,
signed statement of all Inventions and Intellectual property in which Consultant participated
prior to termination of Consultant’s Consultancy by the Company. Consultant hereby designates
the Company as his agent, and grants to the Company a power of attorney with full power of
substitution, which power of attorney shall be deemed coupled with an interest, for the
purposes of effecting the foregoing assignments from the Consultant to the Company.
	 
	5.  	Non-Solicitation. Consultant shall not during the term of his Consultancy or at any time
during the two (2) years following termination of his Consultancy solicit any person who is
employed by or a consultant to the Company or any affiliate or subsidiary of the Company
either during Consultant’s period of Consultancy or during such two (2) year period, to
terminate such person’s employment by or consultancy to the Company, such affiliate or
subsidiary. As used herein the term solicit shall mean requesting, encouraging, assisting or
causing, directly or indirectly, any such Consultant to terminate such person’s employment by
or consultancy

2

 

	   	to the Company, affiliate or subsidiary. Notwithstanding the immediately two preceding
sentences, Consultant shall be free to engage consultants (including lawyers and accountants)
so long as he does not interfere with their prior relationship with the Company.
	 
	6.  	Prohibited Competition. Consultant recognizes and acknowledges the competitive and
proprietary nature of the Company’s business operations. Accordingly, Consultant agrees that,
during the term of his Consultancy and for a period of six (6) months following termination of
his Consultancy, whether such termination is voluntary or involuntary, Consultant shall not,
without the prior written consent of the Company, for himself or on behalf of any other person
or entity, directly or indirectly, either as principal, agent, stockholder, Consultant,
consultant, representative or in any other capacity: (i) own, manage, operate or control, or
be concerned, connected or employed by, or otherwise associate in any manner with, or engage
in or have a financial interest in, any business which offers or performs any of the
services, or researches, develops, manufactures or sells any of the products, provided or
offered by the Company or under development by the Company, or any services or products
designed or marketed primarily to fulfill the same function as any such products or services
anywhere in the world, except that nothing contained herein shall preclude Consultant from
purchasing or owning stock in any such competitive business if such stock is publicly traded,
and provided that Consultant’s holdings do not exceed one percent (1%) of the issued and
outstanding capital stock of such business; or (ii) solicit, divert or appropriate or
attempt to solicit, divert or appropriate any customers or patrons of the Company. If any
part of this section should be determined by a court of competent jurisdiction to be
unreasonable in duration, geographic area, or scope, then this section is intended to and
shall extend only for such period of time, in such geographic area and with respect to such
activity as is determined by such court to be reasonable.
	 
	7.  	Continuing Obligations. Consultant’s obligations under this Agreement shall not be
affected: (i) by any termination of Consultant’s Consultancy, including termination at the
Company’s initiative; nor (ii) by any change in Consultant’s position, title or function with
the Company; nor (iii) by any interruption in Consultancy during which Consultant leaves and
then rejoins the Company within a period of six (6) months. Nothing herein shall be construed
as constituting an employment agreement or an undertaking by the Company to retain
Consultant’s services for any stated period of time.
	 
	8.  	No Conflicting Agreements. Consultant represents and warrants that execution and
performance of this Agreement does not and will not violate, conflict with, or constitute a
default under any contract, commitment, agreement, understanding, arrangements, or
restriction, or any adjudication, order, injunction or finding of any kind by any court or
agency to which Consultant may be a party or by which Consultant may be bound.
	 
	9.  	Remedies. In the event of any breach by Consultant of any of the provisions of this
Agreement, the Company shall be entitled, in addition to monetary damages and to any other
remedies available to the Company under this Agreement and at law, to equitable relief,
including injunctive relief, and to payment by Consultant of all costs incurred by the Company
in enforcement against Consultant of the provisions of this Agreement, including reasonable
attorneys fees.
	 
	10.  	General Provisions.

	 	(a)  	No General Waiver. Waiver of any provision of this Agreement, in whole or in
part, in any one instance shall not constitute a waiver of any other provision in the
same instance, nor any waiver of the same provision in another instance, but each
provision shall continue in full force and effect with respect to any other then-existing
or subsequent breach.
	 
	 	(b)  	Notice. For purposes of this Agreement, notices and all other communications
provided for herein shall be in writing and shall be deemed to have been duly given when
delivered personally or by overnight courier with a receipt obtained therefor or when
mailed by United States registered or certified mail, return receipt requested, postage
prepaid, addressed, if to the Company, to its chief executive officer at the Company’s
principal office, and if to the Consultant, at his residence address,

3

 

	  	  	or to such other address as either party may furnish to the other in writing in
accordance with this Section, except that notices of changes of address shall be
effective upon receipt.
	 
	 	(c)  	Severability. If any provision of this Agreement shall be found to be
invalid, inoperative or unenforceable in law or equity, such finding shall not affect
the validity of any other provisions of this Agreement, which shall be construed,
reformed and enforced to effect the purposes of this Agreement to the fullest extent
permitted by law.
	 
	 	(d)  	Miscellaneous. This Agreement: (i) may be executed in any number of
counterparts, each of which, when executed by both parties to the Agreement shall be
deemed to be an original, and all of which counterparts together shall constitute one
and the same instrument; (ii) shall be governed by and construed under the law of the
State of Maryland, without application of principles of conflicts of laws; (iii) shall
constitute the entire agreement of the parties with respect to the subject matter
hereof, superseding all prior oral and written communications, proposals,
negotiations, representations, understandings, courses of dealing, agreements,
contracts, and the like between the parties in such respect; (iv) may be amended,
modified, or terminated, and any right under this Agreement may be waived in whole or
in part, only by a writing signed by both parties; (v) contains headings only for
convenience, which headings do not form part, and shall not be used in construction,
of this Agreement; (vi) shall bind and inure to the benefit of the parties and their
respective legal representatives, successors and assigns, except that no party may
delegate any of its or his obligations under this Agreement, or assign this Agreement,
without the prior written consent of the other party, except the Company may assign
this Agreement in connection with the merger, consolidation, or sale of all or
substantially all assets of the Company; and (vii) be enforced only in courts located
within the State of Maryland and the parties hereby agree that such courts shall have
venue and exclusive subject matter and personal jurisdiction, and consent to service
of process by registered mail, return receipt requested, or by any other manner
provided by law.

        Executed under seal as of the date first above written.

	 	 	 	 	 
	ON BEHALF OF THERAPEUTIC
	 	 	 	 
	GENOMICS CORPORATION, INC.:

	 	CONSULTANT:	 	 
	 
	 	 	 	 
	/s/ Kenneth C. Carter

	 	/s/ Bradley G. Lorimier	 	 
	 

	 	 	 	 
	Kenneth C. Carter, Ph.D.

	 	Bradley G. Lorimier	 	 
	CEO and President
	 	 	 	 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}]]